ALK and non-small cell lung carcinoma: Over the past decade, the emergence of ALK tyrosine kinase inhibitors (TKIs) has significantly transformed the treatment landscape and outcomes for ALK+ NSCLC patients (Solomon et al., 2014; Shaw et al., 2014; Peters et al., 2017; Camidge et al., 2018; Shaw et al., 2020).